RPRX
HealthcareRoyalty Pharma plc
$39.65
+$0.79 (+2.03%)
Jan 5, 2026
Price History (1Y)
Analysis
Royalty Pharma plc is a biotechnology company in the healthcare sector with a market capitalization of $23.12B and revenue of $2.35B (TTM). The company operates within the industry of Biotechnology. The company's financial health is characterized by high profitability, with gross margin at 106.6% and operating margin at 70.3%. Net income (TTM) stands at $764.96M. Returns on equity (ROE) and assets (ROA) are 13.1% and 5.2%, respectively. The company has a debt-to-equity ratio of 93.19, with cash holdings of $955.04M against debt of $8.97B. The valuation context for Royalty Pharma plc is marked by a price-to-earnings (P/E) ratio of 22.28 (TTM) and a forward P/E of 7.85. The company has reported revenue growth of 7.9% year-over-year, with earnings growth of -45.2%. A dividend yield of 226.0% is accompanied by a payout ratio of 49.7%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Visit website →Key Statistics
- Market Cap
- $23.12B
- P/E Ratio
- 22.28
- 52-Week High
- $41.24
- 52-Week Low
- $25.55
- Avg Volume
- 3.69M
- Beta
- 0.42
- Dividend Yield
- 226.00%
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States